Youssef M Hanna, MD in Port Huron, MI - Medicare Hematology/oncology

Youssef M Hanna, MD is a medicare enrolled "Internal Medicine - Hematology & Oncology" physician in Port Huron, Michigan. He graduated from medical school in 1992 and has 32 years of diverse experience with area of expertise as Hematology/oncology. He is a member of the group practice Beaumont Medical Group- Specialty Services, Huron Medical Center P.c. and his current practice location is 1231 Pine Grove Ave, Ste 2f, Port Huron, Michigan. You can reach out to his office (for appointments etc.) via phone at (810) 982-5200.

Youssef M Hanna is licensed to practice in Michigan (license number 4301061471) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1639115397.

Contact Information

	Youssef M Hanna, MD
	1231 Pine Grove Ave, Ste 2f, Port Huron, MI 48060-3500
	(810) 982-5200
	(810) 982-9776

Physician's Profile

Full Name	Youssef M Hanna
Gender	Male
Speciality	Hematology/oncology
Experience	32 Years
Location	1231 Pine Grove Ave, Port Huron, Michigan
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Youssef M Hanna graduated from medical school in 1992

NPI Data:

NPI Number: 1639115397
Provider Enumeration Date: 06/21/2006
Last Update Date: 10/22/2020

Medicare PECOS Information:

PECOS PAC ID: 5799822243
Enrollment ID: I20091102000462

Medical Identifiers

Medical identifiers for Youssef M Hanna such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1639115397	NPI	-	NPPES
4397059	Medicaid	MI
110G41039	Other	MI	BCBSM
P115104	Other	MI	BCN HANNA

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207RH0003X	Internal Medicine - Hematology & Oncology	4301061471 (Michigan)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Beaumont Hospital, Troy	Troy, MI	Hospital
Mclaren Port Huron	Port huron, MI	Hospital
Beaumont Hospital - Grosse Pointe	Grosse pointe, MI	Hospital
Beaumont Hospital - Farmington Hills	Farmington hills, MI	Hospital
Lake Huron Medical Center	Port huron, MI	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Beaumont Medical Group- Specialty Services	7214299866	787
Huron Medical Center P.c.	0648283929	7

News Archive

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

ExonHit Therapeutics yesterday presented clinical data on the validation set "Alzheimer patients versus healthy controls" for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer's disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer's Disease (CTAD) in Las Vegas, USA.

Congress needs to act to incentivize development of genomic data systems

The latest generation of genomic testing offers a chance for significant improvements in patient care, disease prevention, and possibly even the cost-effectiveness of healthcare, but Congress needs to act to incentivize the development of the massive data systems that doctors and regulators will need in order to make these tests safe and effective for patients.

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

The arrival of COVID-19 has provided a nuclear-level stress test to the American health care system, and our grade isn't pretty: at least 73,000 dead, 1.2 million infected and 30 million unemployed; nursing homes, prisons and meatpacking plants that have become hotbeds of infection.

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Youssef M Hanna allows following entities to bill medicare on his behalf.

Entity Name	Huron Medical Center P.c.
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1447277496 PECOS PAC ID: 0648283929 Enrollment ID: O20060803000493

News Archive

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Entity Name	Beaumont Medical Group- Specialty Services
Entity Type	Part B Supplier - Clinic/group Practice
Entity Identifiers	NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Youssef M Hanna is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Youssef M Hanna, MD 1231 Pine Grove Ave, Suite 2f, Port Huron, MI 48060-3500 Ph: (810) 982-5200	Youssef M Hanna, MD 1231 Pine Grove Ave, Ste 2f, Port Huron, MI 48060-3500 Ph: (810) 982-5200

News Archive

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Internal Medicine Doctors in Port Huron, MI

Mr. Podduturu Sridhar Reddy, M.D., M.P.H. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2615 Electric Avenue, Port Huron, MI 48060 Phone: 810-990-8222 Fax: 810-937-5592
Samir Alsawah, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1231 Pine Grove Ave, Ste 2f, Port Huron, MI 48060 Phone: 810-982-5200 Fax: 810-982-9776
Gloria L Moore, FNP Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 2601 Electric Ave, Port Huron, MI 48060 Phone: 810-216-1500
Subbana G Muthuswami, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2603 Electric Ave, #1, Port Huron, MI 48060 Phone: 810-987-5252 Fax: 810-987-2120
Dr. Virender D Parekh, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1222 10th Ave, Port Huron, MI 48060 Phone: 810-985-9681 Fax: 810-985-3590
Ali H Haidar, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1231 Pine Grove Ave, Suite 2b, Port Huron, MI 48060 Phone: 810-987-5500 Fax: 810-987-6321
Dr. Rafia Khalil, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1201 Stone St Ste 3, Port Huron, MI 48060 Phone: 810-985-5000 Fax: 810-985-3700

Youssef M Hanna, MD - Medicare Hematology/oncology in Port Huron, MI

Contact Information

Physician's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Medicare Reassignments

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Clinical data on the validation set 'Alzheimer patients versus healthy controls' for AclarusDx presented

Congress needs to act to incentivize development of genomic data systems

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Analysis: We knew the coronavirus was coming, yet we failed 5 critical tests

FDA issues Complete Response Letter to Amgen's sBLA for XGEVA

Internal Medicine Doctors in Port Huron, MI